An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab

Annals of Oncology

Volumn 14, Issue 4, 2003, Pages 520-535

  Boye, J ^a   Elter, T ^a   Engert, A ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Chronic lymphocytic leukemia; Clinical studies; Hodgkin's disease; Non Hodgkin's lymphoma; Rituximab

Indexed keywords

BENDAMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTOKINE; CYTOTOXIC AGENT; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; MITOXANTRONE; PREDNISONE; RECOMBINANT ALPHA INTERFERON; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; CHOP PROTOCOL; MONOCLONAL ANTIBODY;

ANGIONEUROTIC EDEMA; ASTHENIA; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; BRONCHOSPASM; CHILL; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEVER; FOLLICULAR LYMPHOMA; HEADACHE; HODGKIN DISEASE; HUMAN; HYPOTENSION; LYMPHOPROLIFERATIVE DISEASE; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PAIN; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; RHINITIS; RIGOR; SIDE EFFECT; STEM CELL TRANSPLANTATION; VASODILATATION; WALDENSTROEM MACROGLOBULINEMIA; CHEMICALLY INDUCED DISORDER; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUTOIMMUNE DISEASES; CHILLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEVER; HODGKIN DISEASE; HUMANS; LYMPHOMA, MANTLE-CELL; LYMPHOMA, NON-HODGKIN; LYMPHOPROLIFERATIVE DISORDERS; MULTIPLE MYELOMA; PREDNISONE; TREATMENT OUTCOME; VINCRISTINE;

EID: 0037819344     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg175     Document Type: Review

References (112)

1. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of pre-defined specificity. Nature 1975; 256: 495-497.
2. Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-445.
3. Press OW, Appelbaum F, Ledbetter JA et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 1987; 69: 584-591.
4. LoBuglio AF, Wheeler RH, Trang J et al. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci USA 1989; 86: 4220-4224.
5. Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte-specific antigen. J Immunol 1980; 125: 1678-1685.
6. Srinivas S, Yook C, Chang V et al. Prevalence of bone marrow CD20 positivity in patients (pts) with multiple myeloma (MM). J Clin Oncol 2001; 20: (Abstr 2687).
7. Anderson DR, Grillo-Lopez A, Varns C et al. Targeted anti-cancer therapy using rituximab, a chimeric CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Trans 1997; 25: 705-708.
8. Tedder TF, Engel P. CD20. A regulator of cell-cycle progression of B lymphocytes. Immunol Today 1994; 15: 450-454.
9. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-2833.
10. Grillo-Lopez AJ, Cheson BD, Horning SJ et al. Response criteria for NHL: impotance of 'normal' lymph node size and correlations with response rates. Ann Oncol 2000; 11: 399-408.
11. Velasquez WS, Jagannath S, Tucker SL et al. Risk classification as the basis for clinical staging of diffuse large-cell lymphoma derived from 10-year survival data. Blood 1989; 74: 551-557.
12. Davis TA, White CA, Grillo-Lopez AJ et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol 1999; 17: 1851-1857.
13. Colombat P, Salles G, Brousse N et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97: 101-106.
14. Hainsworth JD. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: interim follow-up of a multicenter phase II trial. Semin Oncol 2002; 29 (1 Suppl 2): 25-29.
15. Davis TA, Grillo-Lopez AJ, White CA et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000; 18: 3135-3143.
16. Igarashi T, Ohtsu T, Fujii H et al. Re-treatment of relapsed indolent B-cell lymphoma with rituximab. Int J Hematol 2001; 73: 213-221.
17. Davis TA, Czerwinski DK, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res 2000; 6: 317-318.
18. Demidem A, Lam T, Alas S et al. Chimeric anti-CD 20 antibody sensitizes a B-cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997; 12: 177-186.
19. Di Gaetano N, Xiao Y, Erba E et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 2001; 114: 800-809.
20. Alas S, Bonavida B, Emmanouilides C. Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab. Anticancer Res 2000; 20: 2961-2966.
21. Czuczman MS, Fallon A, Mohr A et al. Phase II study of rituximab plus fludarabine in patients (pts.) with low-grade lymphoma. Blood 2001; 98 (Suppl 1): 601 (Abstr 2518A).
22. Czuczman MS, Grillo-Lopez AJ, White CA et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268-276.
23. Freedman AS, Gribben JG, Neuberg D et al. High dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 1996; 88: 2780-2786.
24. Czuczman M, Grillo-Lopez AJ, White CA et al. Progression free survival (PFS) after six years (median) follow-up of the first clinical trial of rituximab/CHOP chemoimmunotherapy. Blood 2001; 98 (Suppl 1): 601a (Abstr 2519A).
25. Rambaldi A, Carlotti E, Baccarani M et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated follicular lymphoma patients. Blood 2001; 98 (Suppl 1): 603a (Abstr 2528A).
26. McLaughlin P, Hagemeister FB, Rodriguez MA et al. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Semin Oncol 2000; 27 (Suppl 12): 37-41.
27. Vitolo U, Boccomini C, Astolfi M et al. Chemoimmunotherapy with fludarabine + mitoxantrone + dexamethasone (FND) and rituximab in indolent non-Hodgkin's lymphoma (NHL): a pilot study to evaluate feasibility, safety, clinical and molecular response. Blood 2001; 98 (Suppl 1): 252 (Abstr 4739A).
28. Hiddemann W, Forstpointner R, Fiedler F et al. Combined immunotherapy (R-FCM) is superior to a fludarabine-containing chemotherapy (FCM) alone in recurrent indolent lymphoma - results of a prospective randomized comparison of the German Low Grade Lymphoma Study Group. Onkologie 2001; 24: 90A.
29. Patel D, Gupta NK, Mehrotra B et al. Rituximab, cyclophosphamide and decadron (RCD) combination is an effective salvage regimen for previously treated low grade lymphoma. J Clin Oncol 2001; 20: (Abstr 2665).
30. Gregory SA, Venugopal P, Adler SS et al. Safety and efficacy of fludarabine and mitoxantrone with rituximab consolidation in untreated advanced low grade non-Hodgkin's lymphoma (LG-NHL). Blood 2001; 98 (Suppl 1): 605a (Abstr 2534A).
31. Weide R, Heymanns J, Gores A, Köppler H. Bendamustine, mitoxantrone and rituximab (BMR): a new effective regimen for refractory or relapsed indolent lymphoma. Leuk Lymphoma 2002; 43: 327-331.
32. Kirchner HH, Gaede B, Steinhauer EU et al. Chemoimmunotherapy with fludarabine, bendamustine and rituximab for relapsed low grade malignant non-Hodgkin's lymphoma. Blood 2001; 98 (Suppl 1): 135a (Abstr 568A).
33. Herold M, Fiedler F, Pasold R et al. Efficacy and toxicity of rituximab plus mitoxantrone, chlorambucil, prednisolone (MCP) versus MCP alone in advanced indolent NHL - interim results of a clinical phase III study of the East German Study Group Hematology/Oncology (OSHO). Blood 2001; 98 (Suppl 1):601 (Abstr 2521A).
34. Basham TY, Race ER, Campbell MJ et al. Synergistic antitumor activity with IFN and monoclonal anti-idiotype antibody for murine B cell lymphoma. Mechanism of action. J Immunol 1988; 141: 2855-2860.
35. Hari P, Venugopal P, Sivaraman S et al. Analysis of time sequence of CD20 antigen expression changes on tumor cells following exposure to cytokines. Blood 2001; 98 (Suppl 1): 228b (Abstr 4634A).
36. Guadagni F, Schlom J, Pothen S et al. Parameters involved in the enhancement of monoclonal antibody targeting in vivo with recombination interferon. Cancer Immunol Immunther 1998; 26: 222-230.
37. Yokota S, Hara H, Luo Y, Seon BK. Synergistic potentiation of in vivo antitumor activity of anti-human T-leukemia immunotoxins by recombinant α-interferon and daunorubicin. Cancer Res 1990; 50: 32-37.
38. Davis TA, Maloney DG, Grillo-Lopez AJ et al. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-α-2a. Clin Cancer Res 2000; 6: 2644-2652.
39. Sacchi S, Frederico M, Vitolo U et al. Clinical activity and safety of combination immunotherapy with interferon-α2a and rituximab in patients with relapsed low-grade non-Hodgkin's lymphoma. Haematologica 2001; 86: 951-958.
40. Kimby E, Geisler C, Hagberg H et al. Rituximab (Mabthera) as single agent and in combination with interferon-α-2a as treatment of untreated and first relapse follicular or other low-grade lymphomas. A randomized phase II study (M39035). Blood 2000; 96 (Suppl 1): 577a (Abstr 2479A).
41. Magni M, Di Nicola M, Devizzi L et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 2000; 96: 864-869.
42. Flinn IW, Jones RJ, Goodrich A et al. Rituximab during autologous stem cell transplantation for lymphoma produces lymphoma free grafts in most patients by PCR and clonogenic assays. Blood 2001; 98 (Suppl 1): 676a (Abstr 2832A).
43. Buckstein RJ, Imrie KR, Spaner D et al. Autologous stem cell transplants combined with rituximab for relapsed follicular lymphoma achieve prolonged clinical and molecular remissions. Blood 2001; 98 (Suppl 1): 680a (Abstr 2846A).
44. Voso MT, Pantel G, Weis M et al. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma. Br J Haematol 2000; 109: 729-735.
45. Brugger W. Improving outcomes in transplantation. Semin Oncol 2002; 29 (2 Suppl 6): 23-26.
46. Maloney DG, Grillo-Lopez AJ, Bodkin DJ et al. IDEC-C2B8: results of a phase I multi-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 3266-3274.
47. Maloney DG, Grillo-Lopez AJ, White CA et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188-2195.
48. Ghielmini M, Schmitz SF, Burki K et al. The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Ann Oncol 2000; 11 (Suppl 1): 123-126.
49. Feuring-Buske M, Kneba M, Unterhalt M et al. IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group. Ann Hematol 2000; 79: 493-500.
50. O'Brien SM, Kantarjian H, Thomas DA et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 2165-2170.
51. Byrd JC, Murphy T, Howard RS et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001; 19: 2153-2164.
52. Piro LT, White CA, Grillo-Lopez AJ et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999; 10: 655-661.
53. Vose JM, Link BK, Grossbard ML et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001; 19: 389-397.
54. Coiffier B, Lepage E, Briere PD et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
55. Coiffier B, Haioun C, Ketterer N et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 1998; 92: 1927-1932.
56. Kewalramani T, Zelenetz A, Bertino J et al. Rituximab significantly increases the complete response rate in patients with relapsed or primary refractory DLBCL receiving ICE as second-line therapy (SLT). Blood 2001; 98 (Suppl 1): 346a (Abstr 1459A).
57. Horwitz SM, Negrin RS, Stockerl-Goldstein KE et al. Phase II trial of rituximab as adjuvant therapy to high dose chemotherapy and peripheral blood stem cell transplantation for relapsed and refractory aggressive non-Hodgkin's lymphomas. Blood 2001; 98 (Suppl 1): 862a (Abstr 3578A).
58. Wilson WH, Gutierrez M, O'Connor P et al. The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose-adjusted EPOCH-R. Semin Oncol 2002; 29 (1 Suppl 2): 41-47.
59. Tsai DE, Moore HCF, Hardy CL et al. Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation. Bone Marrow Transplant 1999; 24: 521-526.
60. Foran JM, Rohatiner AZS, Cunningham D et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000; 18: 317-324.
61. Nguyen DT, Amess JA, Doughty H et al. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. Eur J Haematol 1999; 62: 76-82.
62. Howard OM, Gribben JG, Neuberg DS et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002; 20: 1288-1294.
63. Mangel J, Buckstein R, Imrie K et al. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma. Semin Oncol 2002; 29 (1 Suppl 2): 56-69.
64. Seyfarth B, Sonnen R, Zeis M et al. Mantle cell lymphoma: promising results with upfront stem cell transplantation using the rituximab/TBI/CY high-dose regimen. Blood 2001; 98 (Suppl 1): 679a (Abstr 2841A).
65. Corradini P, Astolfi M, Cherasco C et al. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting. Blood 1997; 89: 724-731.
66. Andersen NS, Donovan JW, Borus JS et al. Failure of immunologic purging in in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. Blood 1997; 90: 4212-4221.
67. Romaguera J, Cabanillas F, Dang NH et al. Mantle cell lymphoma (MCL) - high rates of complete remission (CR) and prolonged failure-free survival (FFS) with Rituxan-HyperCVAD (R-HCVAD) without stem cell transplant (SCT). Blood 2001; 98 (Suppl 1): 726a (Abstr 3030A).
68. Winkler U, Jensen M, Manzke O et al. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC C2B8). Blood 1999; 94: 2217-2224.
69. Huhn D, von Schilling C, Wilhelm M et al. Rituximab therapy of patients with B-cell chronic lymphatic leukemia. Blood 2001; 98: 1326-1331.
70. Manshouri T, Saffer H, Keating M, Albitar M. Clinical relevance of circulating CD20 (cCD20) in patients with chronic lymphocytic leukemia (CLL). Blood 2000; 96 (Suppl 1): 369a (Abstr 1595A).
71. Gupta NK, Patel D, Kavuru S et al. Rituximab, cyclophosphamide and decadron (RCD) is effective in previously treated advanced chronic lymphocytic leukemia (CLL). J Clin Oncol 2001; 20: (Abstr 1133).
72. Schulz H, Klein SK, Rehwald U et al. Phase II study of combined immunotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 2001; 100: 3115-3120.
73. Byrd JC, Peterson BL, Park K et al. Concurrent rituximab and fludarabine has a higher complete response rate than sequential treatment in untreated chronic lymphocytic leukemia (CLL) patients: results from CALGB 9712. Blood 2001; 98 (Suppl 1): 772a (Abstr 3212A).
74. Wierda W, O'Brien S, Albitar M et al. Combined fludarabine, cyclophosphamide, and rituximab achieves a high complete remission rate as initial treatment for chronic lymphocytic leukemia. Blood 2001; 98 (Suppl 1): 771a (Abstr 3210A).
75. Manero GG, O'Brien S, Cortes J et al. Update of results of the combination of fludarabine, cyclophosphamide and rituximab for previously treated patients with chronic lymphocytic leukemia (CLL). Blood 2001; 98 (Suppl 1): 633a (Abstr 2650A).
76. Hainsworth JD, Litchy S, Burris HA, Greco A. Rituximab as first-line and maintenance therapy for patients with small lymphocytic lymphoma (SLL) and chronic lymphocytic leukemia (CLL). Blood 2001; 98 (Suppl 1): 363a (Abstr 1530A).
77. Thomas DA, O'Brien S, Giles FJ et al. Single agent rituxan in early stage chronic lymphocytic leukemia (CLL). Blood 2001; 98 (Suppl 1): 364a (Abstr 1533A).
78. San Miguel JF, Gonzalez M, Gascon A et al. Immunophenotypic heterogeneity of multiple myeloma: influence on the biology and clinical course of the disease. Castellano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies. Br J Haematol 1991; 77: 185-190.
79. Treon SP, Pilarski LM, Belch AR et al. CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J Immunother 2002; 25: 72-81.
80. Hsi E, Hussein MA, Elson P et al. Biologic and clinical evaluation of rituxan (RT) in the management of newly diagnosed multiple myeloma (MM) patients (pts): an update. J Clin Oncol 2001; 20: 1193A.
81. Byrd JC, White CA, Link B et al. Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity. Ann Oncol 1999; 10: 1525-1527.
82. Weber DM, Gavino M, Huh Y et al. Phenotypic and clinical evidence supports rituximab for Waldenström's macroglobulinemia. Blood 1999; 94 (Suppl 1): 125a (Abstr 551A).
83. Weide R, Heymanns J, Köppler H. The polyneuropathy associated with Waldenström's macroglobulinaemia can be treated effectively with chemotherapy and the anti-CD20 monoclonal antibody rituximab. Br J Haematol 2000; 109: 838-841.
84. Treon SP, Agus DB, Link B et al. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macrcoglobulinemia. J Immunother 2001; 24: 272-279.
85. Dimopoulos MA, Zervas C, Zomas A et al. Treatment of Waldenstrom's macroglobulinemia with rituximab. J Clin Oncol 2002; 20: 2327-2333.
86. Heinzerling L, Dummer R, Kempf W et al. Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma. Arch Dermatol 2000; 136: 374-378.
87. Heinzerling LM, Urbanek M, Funk JO et al. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 anti-body (rituximab) in patients with primary cutaneous B-cell lymphoma. Cancer 2000; 89: 1835-1844.
88. Horwitz SM, Tsai D, Twist C et al. Rituximab is effective therapy for post-transplant lymphoproliferative disorder (PTLD) not responding to reduction in immunosuppression: a prospective trial in adults and children. J Clin Oncol 2001; 20: 1134A.
89. Kentos A, Knoop C, Wissing M et al. Anti-CD20 monoclonal antibody as first-line treatment of post-transplant B-lymphoproliferative disorders in solid organ transplant recipients. A report of 8 cases observed in a single center. Blood 2001; 98 (Suppl 1): 344a(Abstr 1451A).
90. Morrison VA, Bartlett N, Dunn DL, Peterson BA. Rituximab therapy for post-transplant lymphoproliferative disorders (PTLD): preliminary outcome results. J Clin Oncol 2001; 20: 1177A.
91. Shah PK, Ifthikharuddin J, Mintz M et al. 2-Chlorodeoxyadenosine (2-CDA) with weekly rituximab and granulocyte-macrophage colony stimulating factor (GM-CSF): a highly effective regimen for advanced B-cell lymphoproliferative disorders (BLPD). Blood 2001; 98 (Suppl 1): 249b (Abstr 4726A).
92. Kuehnle I, Huls MH, Liu Z et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 2000; 95: 1502-1505.
93. Gruhn B, Meerbach A, Häfer R et al. Early diagnosis and pre-emptive therapy Epstein-Barr virus-associated lymphoproliferative disease following hematopoietic stem cell transplantation. Blood 2001; 98 (Suppl 1): 393a (Abstr 1655A).
94. Rassidakis GZ, Medeiros LJ, Viviani S et al. CD 20 expression on Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcome. J Clin Oncol 2002; 20: 1278-1287.
95. Rehwald U, Engert A, Diehl V. Monoclonal anti-CD20 antibody Rituximab (Rituxan) for treatment of CD20-positive Hodgkin's lymphoma: The German experience. Blood 2000; 96 (Suppl 1): 729a (Abstr 3153A).
96. Lucas JB, Hoppe RT, Horwitz RM et al. Rituximab is active in lymphocyte predominant Hodgkin's disease. Blood 2000; 96 (Suppl 1): 831a (Abstr 3592A).
97. Younes A, Romaguera J, Hagemeister F et al. Depletion of normal B-lymphocytes by rituximab therapy alters serum cytokine levels, resolves B-symptoms and induces clinical remissions in patients with relapsed classical Hodgkin's disease (HD). Blood 2001; 98 (Suppl 1): 132a (Abstr 555A).
98. Saleh MN, Moore M, Feinberg B et al. A pilot study of anti-CD20 MoAb rituximab in patients with refractory immune thrombocytopenic purpura (ITP). Blood 2001; 98 (Suppl 1): 521a (Abstr 2179A).
99. Giagounidis AAN, Anhuf J, Schneider P et al. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 antibody rituximab. Blood 2001; 98 (Suppl 1): 523a (Abstr 2187A).
100. Perotta A, Abuel C. Update of response to rituximab of chronic relapsing ITP. Blood 1999; 94 (Suppl 1): 82b (Abstr 3528).
101. Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001; 98: 952-957.
102. Berentsen S, Tjonnfjord GE, Gjertsen BT et al. Rituxan (Rituximab) therapy for chronic cold agglutinin disease. Blood 2000; 96 (Suppl 1): 730 (Abstr 3156A).
103. Lee E, Zamkoff KW, Gentile TC, Zimrin A. Rituximab in the treatment of auto-immune hemolytic anemia (AIHA). Blood 2000; 96 (Suppl 1): 596a (Abstr 2560A).
104. Quartier P, Brethon P, Philippet P et al. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 2001; 358: 1511-1513.
105. Gupta NK, Patel DV, Kavuru S et al. Re-treatment with a rituximab based therapy is highly effective in autoimmune hemolytic anemia (AIHA) associated with chronic lymphocytic leukemia (CLL). Blood 2001; 98 (Suppl 1): 363a (Abstr 1529A).
106. Ratanatharathorn V, Bociek RG, Pavletic SZ et al. Prior therapy with anti-CD20 chimeric antibody (Rituximab) may decrease the risk of acute graft-versus-host disease (GVHD) in patients with non-Hodgkin's lymphoma receiving allogeneic stem cell transplantation. Blood 2000; 96 (Suppl 1): 391a (Abstr 1688).
107. Herold M, Schnohr S, Bittrich H. Efficacy and safety of a combined rituximab chemotherapy during pregnancy. J Clin Oncol 2001; 19: 3439.
108. Ng HJ, Lim LC. Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report. Ann Hematol 2001; 80: 549-552.
109. Hamaki T, Kami M, Kusumi E et al. A feasibility study of rituximab for patients with hepatitis B or C virus infection in the treatment of non-Hodgkin's lymphoma. Blood 2001; 98 (Suppl 1): 242b (Abstr 4695A).
110. Maeda T, Yamada Y, Tawara M et al. Successful treatment with a chimeric anti-CD20 monoclonal antibody (IDEC C2-B8, rituximab) for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody. Int J Hematol 2001; 74: 70-75.
111. Voog E, Brice P, Cartrin J et al. Acute agranulocytosis (AA) in three patients treated with rituximab for non-Hodgkin's lymphoma (NHL). Blood 2001; 98 (Suppl 1): 236b (Abstr 4668A).
112. Rituximab 1999 package insert.